This headline appears to refer to a specific group of medicines, not all drugs.In March 2026, the European Medicines Agency recommended withdrawing levamisole-containing medicines from the EU market after a safety review found that they can cause leukoencephalopathy, a rare but serious disorder that damages the brain’s white matter. The review concluded that:
- The condition can occur after a single dose of levamisole.
- Symptoms may appear from one day to several months after treatment.
- The risk is unpredictable, and no reliable way was found to identify who is at higher risk.
- Because safer alternatives are available for treating parasitic worm infections, the benefits of levamisole no longer outweighed the risks.
The headline, however, is misleading because it says “the drugs” without identifying levamisole. It also uses the phrase “brain damage”, whereas the EMA specifically discussed leukoencephalopathy, a rare neurological condition that affects the brain’s white matter. While this condition can be severe and even life-threatening, the headline omits the fact that it is rare and refers to one specific medicine, not medications in general.
So the accurate takeaway is:
- ✅ The EMA did recommend withdrawing levamisole-containing medicines from the EU market.
- ✅ The review found that leukoencephalopathy can occur even after a single dose.
- ❌ The headline is misleading if it implies that many drugs—or all drugs—have been recalled for causing brain damage after one dose.
